Overcoming EGFR T790M-based Tyrosine Kinase Inhibitor Resistance with an Allele-specific DNAzyme

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the main therapeutic agents used to treat non–small-cell lung cancer patients harboring EGFR-activating mutations. However, most of these patients will eventually develop resistance, 50% of which are due to a secondary mut...

Descripción completa

Detalles Bibliográficos
Autores principales: Lai, Wei-Yun, Chen, Chi-Yuan, Yang, Shuenn-Chen, Wu, Jer-Yuarn, Chang, Cheng-Ju, Yang, Pan-Chyr, Peck, Konan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3982196/
https://www.ncbi.nlm.nih.gov/pubmed/24594844
http://dx.doi.org/10.1038/mtna.2014.3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3982196/
https://www.ncbi.nlm.nih.gov/pubmed/24594844
http://dx.doi.org/10.1038/mtna.2014.3

Ejemplares similares